Long-Term Outcomes of Previously Treated Adult and Adolescent Patients with Severe Hemophilia A Receiving Prophylaxis with Extended Half-Life FVIII Treatments: An Economic Analysis from a United Kingdom Perspective
Gary Benson,1 Tim Morton,2 Huw Thomas,3 Xin Ying Lee4 1Northern Ireland Haemophilia Comprehensive Care Centre and Thrombosis Unit, Belfast City Hospital, Belfast, UK; 2DRG, Bicester, UK; 3Biopharm, Novo Nordisk Ltd, Gatwick, UK; 4Biopharm Access, Novo Nordisk A/S, Søborg, DenmarkCorrespon...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2021-01-01
|
| Series: | ClinicoEconomics and Outcomes Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/long-term-outcomes-of-previously-treated-adult-and-adolescent-patients-peer-reviewed-article-CEOR |
| _version_ | 1818961572548050944 |
|---|---|
| author | Benson G Morton T Thomas H Lee XY |
| author_facet | Benson G Morton T Thomas H Lee XY |
| author_sort | Benson G |
| collection | DOAJ |
| description | Gary Benson,1 Tim Morton,2 Huw Thomas,3 Xin Ying Lee4 1Northern Ireland Haemophilia Comprehensive Care Centre and Thrombosis Unit, Belfast City Hospital, Belfast, UK; 2DRG, Bicester, UK; 3Biopharm, Novo Nordisk Ltd, Gatwick, UK; 4Biopharm Access, Novo Nordisk A/S, Søborg, DenmarkCorrespondence: Xin Ying LeeNovo Nordisk A/S, Vandtårnsvej 114, Søborg DK-2860, DenmarkTel +45 30777030Email xlee@novonordisk.comBackground: The standard of care for patients with hemophilia A is prophylaxis with factor VIII (FVIII) therapies. Extended half-life (EHL) FVIII products offer a reduced infusion burden compared with standard FVIII treatments. However, comparative evidence between EHLs is lacking.Objective: To develop a pharmacodynamic–pharmacokinetic decision model to predict comparative bleed outcomes of adolescents and adults with hemophilia A receiving treatment with various EHL FVIII therapies, capturing differences in cumulative bleeding episodes, breakthrough bleed resolution and resource costs, as well as quality-adjusted life years (QALYs).Methods: The patient population from the pathfinder 2 Phase III clinical trial was used to understand the link between FVIII levels and annual bleeding rates (ABRs). Pharmacokinetic/pharmacodynamic modeling was subsequently applied to estimate FVIII levels for four EHL FVIII treatments (turoctocog alfa pegol [Esperoct®], rurioctocog alfa pegol [Adynovi®], efmoroctocog alfa [Elocta®], and damoctocog alfa pegol [Jivi®]) to predict comparative ABRs. FVIII consumption costs (due to prophylactic treatment and breakthrough bleed resolution) and resource costs, as well as QALYs, were subsequently estimated from a UK NHS perspective over a 70-year time horizon.Results: Turoctocog alfa pegol prophylaxis resulted in 8– 19% fewer cumulative bleeding episodes versus comparators in the base case scenario. Assuming parity in annual prophylaxis costs, turoctocog alfa pegol prophylaxis reduced the cost of product and resource use to resolve a breakthrough bleed by 9– 25% versus comparators. Prophylaxis with turoctocog alfa pegol was also associated with the most QALYs, representing a discounted QALY gain of 0.35– 1.05 compared with the other treatments.Conclusion: Using a pharmacodynamic–pharmacokinetic decision model, turoctocog alfa pegol prophylaxis was associated with fewer cumulative bleeds, as well as lower product and resource costs related to resolving a breakthrough bleed and most QALYs versus comparators.Keywords: hemophilia A, prophylaxis, factor VIII, FVIII, cost-effectiveness model, turoctocog alfa pegol, Esperoct® |
| first_indexed | 2024-12-20T12:15:34Z |
| format | Article |
| id | doaj.art-1e33f88a5eea44048bb9c63d8865b386 |
| institution | Directory Open Access Journal |
| issn | 1178-6981 |
| language | English |
| last_indexed | 2024-12-20T12:15:34Z |
| publishDate | 2021-01-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | ClinicoEconomics and Outcomes Research |
| spelling | doaj.art-1e33f88a5eea44048bb9c63d8865b3862022-12-21T19:41:08ZengDove Medical PressClinicoEconomics and Outcomes Research1178-69812021-01-01Volume 13395161299Long-Term Outcomes of Previously Treated Adult and Adolescent Patients with Severe Hemophilia A Receiving Prophylaxis with Extended Half-Life FVIII Treatments: An Economic Analysis from a United Kingdom PerspectiveBenson GMorton TThomas HLee XYGary Benson,1 Tim Morton,2 Huw Thomas,3 Xin Ying Lee4 1Northern Ireland Haemophilia Comprehensive Care Centre and Thrombosis Unit, Belfast City Hospital, Belfast, UK; 2DRG, Bicester, UK; 3Biopharm, Novo Nordisk Ltd, Gatwick, UK; 4Biopharm Access, Novo Nordisk A/S, Søborg, DenmarkCorrespondence: Xin Ying LeeNovo Nordisk A/S, Vandtårnsvej 114, Søborg DK-2860, DenmarkTel +45 30777030Email xlee@novonordisk.comBackground: The standard of care for patients with hemophilia A is prophylaxis with factor VIII (FVIII) therapies. Extended half-life (EHL) FVIII products offer a reduced infusion burden compared with standard FVIII treatments. However, comparative evidence between EHLs is lacking.Objective: To develop a pharmacodynamic–pharmacokinetic decision model to predict comparative bleed outcomes of adolescents and adults with hemophilia A receiving treatment with various EHL FVIII therapies, capturing differences in cumulative bleeding episodes, breakthrough bleed resolution and resource costs, as well as quality-adjusted life years (QALYs).Methods: The patient population from the pathfinder 2 Phase III clinical trial was used to understand the link between FVIII levels and annual bleeding rates (ABRs). Pharmacokinetic/pharmacodynamic modeling was subsequently applied to estimate FVIII levels for four EHL FVIII treatments (turoctocog alfa pegol [Esperoct®], rurioctocog alfa pegol [Adynovi®], efmoroctocog alfa [Elocta®], and damoctocog alfa pegol [Jivi®]) to predict comparative ABRs. FVIII consumption costs (due to prophylactic treatment and breakthrough bleed resolution) and resource costs, as well as QALYs, were subsequently estimated from a UK NHS perspective over a 70-year time horizon.Results: Turoctocog alfa pegol prophylaxis resulted in 8– 19% fewer cumulative bleeding episodes versus comparators in the base case scenario. Assuming parity in annual prophylaxis costs, turoctocog alfa pegol prophylaxis reduced the cost of product and resource use to resolve a breakthrough bleed by 9– 25% versus comparators. Prophylaxis with turoctocog alfa pegol was also associated with the most QALYs, representing a discounted QALY gain of 0.35– 1.05 compared with the other treatments.Conclusion: Using a pharmacodynamic–pharmacokinetic decision model, turoctocog alfa pegol prophylaxis was associated with fewer cumulative bleeds, as well as lower product and resource costs related to resolving a breakthrough bleed and most QALYs versus comparators.Keywords: hemophilia A, prophylaxis, factor VIII, FVIII, cost-effectiveness model, turoctocog alfa pegol, Esperoct®https://www.dovepress.com/long-term-outcomes-of-previously-treated-adult-and-adolescent-patients-peer-reviewed-article-CEORhemophilia aprophylaxisfactor viii (fviii)cost-effectiveness modelturoctocog alfa pegolesperoct® |
| spellingShingle | Benson G Morton T Thomas H Lee XY Long-Term Outcomes of Previously Treated Adult and Adolescent Patients with Severe Hemophilia A Receiving Prophylaxis with Extended Half-Life FVIII Treatments: An Economic Analysis from a United Kingdom Perspective ClinicoEconomics and Outcomes Research hemophilia a prophylaxis factor viii (fviii) cost-effectiveness model turoctocog alfa pegol esperoct® |
| title | Long-Term Outcomes of Previously Treated Adult and Adolescent Patients with Severe Hemophilia A Receiving Prophylaxis with Extended Half-Life FVIII Treatments: An Economic Analysis from a United Kingdom Perspective |
| title_full | Long-Term Outcomes of Previously Treated Adult and Adolescent Patients with Severe Hemophilia A Receiving Prophylaxis with Extended Half-Life FVIII Treatments: An Economic Analysis from a United Kingdom Perspective |
| title_fullStr | Long-Term Outcomes of Previously Treated Adult and Adolescent Patients with Severe Hemophilia A Receiving Prophylaxis with Extended Half-Life FVIII Treatments: An Economic Analysis from a United Kingdom Perspective |
| title_full_unstemmed | Long-Term Outcomes of Previously Treated Adult and Adolescent Patients with Severe Hemophilia A Receiving Prophylaxis with Extended Half-Life FVIII Treatments: An Economic Analysis from a United Kingdom Perspective |
| title_short | Long-Term Outcomes of Previously Treated Adult and Adolescent Patients with Severe Hemophilia A Receiving Prophylaxis with Extended Half-Life FVIII Treatments: An Economic Analysis from a United Kingdom Perspective |
| title_sort | long term outcomes of previously treated adult and adolescent patients with severe hemophilia a receiving prophylaxis with extended half life fviii treatments an economic analysis from a united kingdom perspective |
| topic | hemophilia a prophylaxis factor viii (fviii) cost-effectiveness model turoctocog alfa pegol esperoct® |
| url | https://www.dovepress.com/long-term-outcomes-of-previously-treated-adult-and-adolescent-patients-peer-reviewed-article-CEOR |
| work_keys_str_mv | AT bensong longtermoutcomesofpreviouslytreatedadultandadolescentpatientswithseverehemophiliaareceivingprophylaxiswithextendedhalflifefviiitreatmentsaneconomicanalysisfromaunitedkingdomperspective AT mortont longtermoutcomesofpreviouslytreatedadultandadolescentpatientswithseverehemophiliaareceivingprophylaxiswithextendedhalflifefviiitreatmentsaneconomicanalysisfromaunitedkingdomperspective AT thomash longtermoutcomesofpreviouslytreatedadultandadolescentpatientswithseverehemophiliaareceivingprophylaxiswithextendedhalflifefviiitreatmentsaneconomicanalysisfromaunitedkingdomperspective AT leexy longtermoutcomesofpreviouslytreatedadultandadolescentpatientswithseverehemophiliaareceivingprophylaxiswithextendedhalflifefviiitreatmentsaneconomicanalysisfromaunitedkingdomperspective |